 Connection
Daniel LaBarbera to Drug Design
This is a "connection" page, showing publications Daniel LaBarbera has written about Drug Design.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.575 |
|
|
|
-
Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
Score: 0.185
-
Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203.
Score: 0.159
-
Li L, Chang KC, Zhou Y, Shieh B, Ponder J, Abraham AD, Ali H, Snow A, Petrash JM, LaBarbera DV. Design of an amide N-glycoside derivative of ?-glucogallin: a stable, potent, and specific inhibitor of aldose reductase. J Med Chem. 2014 Jan 09; 57(1):71-7.
Score: 0.105
-
LaBarbera DV, Reid BG, Yoo BH. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov. 2012 Sep; 7(9):819-30.
Score: 0.095
-
Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WA, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. J Med Chem. 2016 Jan 14; 59(1):480-5.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|